Delayed Australian S.E. 08:55:37 2024-05-07 pm EDT 5-day change 1st Jan Change
0.027 AUD 0.00% Intraday chart for Uscom Limited 0.00% -34.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Uscom Narrows Loss in Fiscal H1 MT
Uscom Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Uscom Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Tranche Update on Uscom Limited's Equity Buyback Plan announced on May 8, 2023. CI
Uscom Limited's Equity Buyback announced on May 8, 2023, has expired with 11,266,885 shares, representing 5.67% for AUD 0.62 million. CI
Uscom Limited announces an Equity Buyback for 19,676,833 shares, representing 9.91% for AUD 1.08 million. CI
Uscom Limited authorizes a Buyback Plan. CI
Uscom Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Uscom's Chinese Subsidiary Secures Innovative SME Designation MT
Australian Shares Retreat After Central Bank Raises Cash Rate Target to 2.35% MT
Uscom's Heart Monitor Secures Inclusion to the Emergency Medicine Guidelines in China; Shares Jump 7% MT
Uscom Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Uscom Posts 19% Decline in Fiscal Q4 Revenue MT
Uscom's Chinese Subsidiary Granted Regulatory NMPA Acceptance for SpiroSonic Spirometers MT
Uscom Limited Files 510K Application CI
Uscom Enters Product Manufacturing Deal in China with Foxconn MT
Uscom Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Uscom Secures Chinese Patents for Cardiac Monitoring Technology; Shares Climb 17% MT
Uscom Limited Announces issuance of Ten-Year China Patents for USCOM 1A CI
Uscom, US-based Koneksa Extend Partnership over Digital Patient-Monitoring Technology MT
Uscom and US Koneksa Extend Technology Partnership CI
Uscom : Validates Accuracy of Blood Pressure Monitor Product to Detect Atrial Fibrillation MT
Uscom Limited Releases Details of A Study Confirming the High Accuracy of the Uscom BP+ Central Blood Pressure Monitor CI
Uscom Limited Reports Earnings Results for the Full Year Ended June 30, 2021 CI
Uscom Limited Announces Five New Software Copyrights for BP Plus in China CI
Chart Uscom Limited
More charts
Uscom Limited is an Australia-based medical technology company that specializes in the development and marketing of non-invasive cardiovascular and pulmonary medical devices. The Company sells two cardiovascular products, the USCOM 1A cardiac output monitor and the Uscom BP+ central blood pressure monitor and a series of pulmonary products, the Uscom SpiroSonic spirometers. The USCOM 1A is a non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler ultrasound to detect abnormalities and guide treatment. The BP+ is a supra-systolic oscillometric central blood pressure monitor, which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. Uscom SpiroSonic digital ultrasonic spirometers are digital, pulmonary function testing devices based on multi-path ultrasound technology. It has geographic sales and distribution segments, which include Australia, Asia, the Americas and Europe.
More about the company
  1. Stock Market
  2. Equities
  3. UCM Stock
  4. News Uscom Limited
  5. Uscom's Heart Monitor Secures Inclusion to the Emergency Medicine Guidelines in China; Shares Jump 7%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW